The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

City of Hope’s investigational COVID-19 vaccine generates robust immune response

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

A COVID-19 investigational vaccine, developed by City of Hope scientists and now licensed to GeoVax Labs Inc., produced a robust neutralizing antibody and T cell response against SARS-CoV-2 with no significant side effects in a phase I clinical trial led by John Zaia, Aaron D. Miller and Edith Miller Chair for Gene Therapy. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Sponsored

At City of Hope, our path to innovation includes surgical simulations in space, diverse genomics data—and more

Earlier this week at City of Hope, we celebrated World Cancer Day by announcing ambitious solutions to tackle some of the most pressing challenges in cancer care. This includes groundbreaking advancements in microbiome research aimed at improving cancer survival, increased emphasis on cancers that disproportionately affect women and people of color, and enhanced access to advanced cancer treatment.
By City of Hope
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account